Press releases

InDex Pharmaceuticals Strengthens IP Position for Kappaproct

- Novel patent for Phase III lead drug candidate filed in the EU, US - Stockholm, August 30, 2012 – InDex Pharmaceuticals today announced the filing of a new patent with the United States Patent and Trademark Office and with the European Patent Office. The company thereby continues to strengthen the c...

Read more

InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member

Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke Pedersen has been appointed as a new member of the Board of Directors. Mr. Pedersen brings to InDex Pharmaceuticals ov...

Read more

InDex Pharmaceuticals Expands Management Team

InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions to its management team: Pernilla Sandwall has been appointed as Head of Clinical Operations and Thomas K...

Read more

InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct

TLR9 Agonist for the Treatment of Chronic, Active, Treatment-Refractory Ulcerative Colitis Stockholm, March 6, 2012 - InDex Pharmaceuticals today announced the start of the COLLECT trial, a European multicenter Phase III study to evaluate the effectiveness and safety of Kappaproct for the treatment of...

Read more